Allovir Inc at Bank of America Global Healthcare Conference Transcript
Good morning, and thank you guys for joining us here today. My name is Cameron Bozdog, and I'm part of Jason Zemansky's SMID cap biotech team at Bank of America. I'm very pleased to introduce Dr. Diana Brainard, CEO of AlloVir. Good morning. To start, perhaps, can you give us a quick overview of AlloVir and your VST therapies for those who maybe aren't as familiar.
Sure. Great to be here. Thanks for the invitation. My name is Diana Brainard, if you didn't catch that, and I'm CEO of AlloVir. At AlloVir, we're a late clinical stage biotech company focused on virus-specific T-cell therapy. That's nongene-edited cell therapy for immunocompromised patients who lack the immunity to fend off these infections on their own. And our lead program is in Phase III. And I'm sure we'll get to that in a moment.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
